India has issued a public health notice urging vigilance and reporting of adverse reactions linked to semaglutide and other GLP-1 drugs used for diabetes and weight loss.
IPC has urged patients to closely monitor and report any adverse reactions
May 25, 2026
07:52 pm
What's the storyThe Indian Pharmacopoeia Commission (IPC) has issued an urgent public health notice regarding the safety of glucagon-like peptide-1 (GLP-1) drugs.
This includes popular medications such as Semaglutide, Dulaglutide, Liraglutide, and Tirzepatide.
A month after desi Ozempic's debut, vitamin market expands 10%
How GLP-1s are more than just weight-loss wonders – but not without risk
Novo Nordisk launches higher-dose Wegovy for those seeking greater weightloss
Dr. Reddy’s launches Semaglutide tablets in India
Pharmacy ordered to recall unregistered weight-loss medicines after raid
Regulator cracks down on illegal weight-loss drugs as demand booms
India’s health ministry warned Tuesday of the risks of unregulated use of weight-loss drugs, as low-cost generic versions hit the…
NEW DELHI: India’s Health Ministry warned on Tuesday of the unregulated use of weight-loss drugs, as cheap generic versions of…
Last week’s expiry of the patent for semaglutide—the active ingredient in Novo Nordisk’s blockbuster drugs Wegovy and Ozmepic…
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
Generic semaglutide increases accessibility, but doctors caution against misuse and quality concerns
Telangana DCA warns against unsupervised semaglutide use, stressing the importance of medical supervision and safe purchasing…
